Diabetes Mellitus News and Research

RSS
Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
RYGB surgery increases insulin activity in diabetes mellitus patients

RYGB surgery increases insulin activity in diabetes mellitus patients

CHD mortality rate in Ontario decreased by 35%: Study

CHD mortality rate in Ontario decreased by 35%: Study

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Harbor BioSciences reports encouraging results from Triolex Phase IIa trials

Harbor BioSciences reports encouraging results from Triolex Phase IIa trials

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

FDA assigns BYDUREON new PDUFA action date of October 22, 2010

OSIR reports net income of $15.7M for fourth-quarter 2009 compared to net loss of $7.8M in 2008: MicroStockProfit.com

OSIR reports net income of $15.7M for fourth-quarter 2009 compared to net loss of $7.8M in 2008: MicroStockProfit.com

Researchers analyze spine surgery patients' existing comorbdities in relationship to hospital stay, costs

Researchers analyze spine surgery patients' existing comorbdities in relationship to hospital stay, costs

ChemoCentryx reports positive data with Traficet-EN in Crohn's disease trial

ChemoCentryx reports positive data with Traficet-EN in Crohn's disease trial

Osiris Therapeutics' Prochymal granted FDA Orphan Drug Designation

Osiris Therapeutics' Prochymal granted FDA Orphan Drug Designation

Study highlights high prevalence of GDM during pregnancy

Study highlights high prevalence of GDM during pregnancy

New classification of depressive subtypes of depression proposed

New classification of depressive subtypes of depression proposed

EHR with controlled interventions can produce optimal BP control, reduce mortality

EHR with controlled interventions can produce optimal BP control, reduce mortality

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Roche announces results of phase III T-emerge 3 study of taspoglutide in diabetics

Roche announces results of phase III T-emerge 3 study of taspoglutide in diabetics

DRCR Network study finds new treatment more effective

DRCR Network study finds new treatment more effective

Better vision ahead for many diabetic retinopathy patients

Better vision ahead for many diabetic retinopathy patients

Cedars-Sinai Heart Institute presents new findings on heart transplantation rejection factors

Cedars-Sinai Heart Institute presents new findings on heart transplantation rejection factors

Study finds AFREZZA comparable to standard of care insulin therapy

Study finds AFREZZA comparable to standard of care insulin therapy

AFREZZA Inhalation Powder reduces incidence of hypoglycemia in patients with Type 1 diabetes

AFREZZA Inhalation Powder reduces incidence of hypoglycemia in patients with Type 1 diabetes

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.